

1 **The adipocyte hormone leptin sets the emergence of hippocampal inhibition in mice.**

2

3 C. Dumon^{1#}, D. Diabira¹, I. Chudotvorova¹, F. Bader^{1,2}, G.S. Sahin³, J. Zhang⁴, C. Porcher¹,
4 G. Wayman³, I. Medina¹, and J-L Gaiarsa^{1*}.

5 ¹ Aix-Marseille University UMR 1249, INSERM (Institut National de la Santé et de la
6 Recherche Médicale) Unité 1249, INMED (Institut de Neurobiologie de la Méditerranée),
7 Parc Scientifique de Luminy, Marseille, France.

8 ²Plateforme Post-Génomique, INMED, 13273 Marseille, France

9 ³Program in Neuroscience, Department of Integrative Physiology and Neuroscience,
10 Washington State University, Pullman, WA, USA.

11 ⁴Institute of Biochemical and Clinical Sciences, University of Exeter Medical School,
12 Hatherly Laboratory, Exeter, EX4 4PS, UK.

13

14 *Correspondence to: jean-luc.gaiarsa@inserm.fr

15 #present address : Neurochlore Parc Scientifique et Technologique de Luminy, Bâtiment
16 Beret Delaage, Zone Luminy Entreprises Biotech, Case 922, 163 avenue de Luminy, 13288
17 MARSEILLE cedex 09. dumon@neurochlore.fr.

18

19 **Short title:** Excess leptin delays brain development in mice.

20 **Key words:** GABA, KCC2, chloride homeostasis, maternal obesity.

21 **Abstract**

22 Brain computations rely on a proper balance between excitation and inhibition which
23 progressively emerges during postnatal development in rodent. γ -aminobutyric acid (GABA)
24 neurotransmission supports inhibition in the adult brain but excites immature rodent neurons.
25 Alterations in the timing of the GABA switch contribute to neurological disorders, so
26 unveiling the involved regulators may be a promising strategy for treatment. Here we show
27 that the adipocyte hormone leptin sets the tempo for the emergence of GABAergic inhibition
28 in the newborn rodent hippocampus. In the absence of leptin signaling, hippocampal neurons
29 show an advanced emergence of GABAergic inhibition. Conversely, maternal obesity
30 associated with hyperleptinemia delays the excitatory to inhibitory switch of GABA action in
31 offspring. This study uncovers a developmental function of leptin that may be linked to the
32 pathogenesis of neurological disorders and helps understanding how maternal environment
33 can adversely impact offspring brain development.

34

35

36 **Introduction**

37 Most brain computations rely on a proper balance between excitation and inhibition,
38 which progressively emerges during development. The γ -aminobutyric acid (GABA) is the
39 main inhibitory transmitter in the adult brain. However, in rodents, at fetal and postnatal
40 stages, GABA induces a membrane depolarization due to elevated intracellular chloride
41 concentration ($[Cl^-]_i$) (Ben Ari et al., 2007; Sato et al., 2017; Owens and Kriegstein, 2002).
42 During the second postnatal week of life, the functional expression of the chloride extruder,
43 K^+ - Cl^- type 2 co-transporter (KCC2), causes $[Cl^-]_i$ to decrease and consequently shifts the
44 chloride-dependent GABAergic responses towards a more hyperpolarized value (Rivera et al.,
45 1999). This developmental sequence is likely shifted toward fetal life in humans (Chen and
46 Kriegstein, 2015; Sedmak et al., 2016). Rodent studies showed that defective chloride
47 homeostasis plays a role in phenotypes associated with autism spectrum disorders (ASD)
48 (Tyzio et al., 2014; He et al., 2014), Rett syndrome (Banerjee et al., 2016; El-Khoury et al.,
49 2014), Down syndrome (Deidda et al., 2015) and Huntington's disease (Dargaei et al., 2018).
50 Conversely, pharmacological manipulations aimed at restoring low $[Cl^-]_i$ improve
51 neurological symptoms in rodents (Tyzio et al., 2014; Deidda et al., 2015; Banerjee et al.,
52 2016; Dargaei et al., 2018) and humans (Lemonnier et al., 2017). Therefore, unveiling the
53 mechanisms controlling the schedule of the GABA developmental sequence is decisive to
54 identify molecular targets to correct abnormal developmental trajectories.

55 Leptin is a 16kDa cytokine produced and secreted mainly by the adipose tissue. In the
56 adult, leptin regulates body weight and reproduction acting on specific hypothalamic nuclei
57 (Ahima and Flier, 2000). However, rodent studies show that leptin can act beyond this
58 classical role and may function as a neurotrophic signal (Bouret et al., 2004; Harvey, 2013;
59 Guimond et al., 2014; Briffa et al., 2015). In both humans and rodents leptin levels surge
60 during intense period of neuronal growth and synaptogenesis. Leptin levels remain elevated in

61 children with early onset ASD (Rodrigues et al., 2014), Rett syndrome (Blardi et al., 2009)
62 and Fragile X syndrome (Lisik et al., 2016). Likewise, maternal obesity which is associated
63 with hyperleptinemia heightens the risk of ASD and other neuropsychiatric disorders in
64 children (Wang et al., 2016; Rivera et al., 2015). These observations suggest that excess leptin
65 early in life may play a role in neuropsychiatric disorders in humans.

66 Here we examined how leptin impacts the GABAergic developmental sequence in the
67 rodent hippocampus. We provide evidence that leptin controls the depolarizing-to-
68 hyperpolarizing GABA switch during postnatal development and that maternal obesity
69 associated with hyperleptinemia delays the GABA switch in offspring.

70

71


72 **Results**

73 **Advanced onset of GABAergic inhibition in leptin-receptor deficient mice**

74 We first compared the efficacy of GABA_A receptor signaling in newborn long-form
75 leptin-receptor (LepRb, the only leptin receptor able to activate intracellular pathway (Ahima
76 and Flier, 2000) deficient (*db/db*) and wild type (wt) mice. To this aim we obtained non-
77 invasive loose cell attached recordings of CA3 pyramidal neurons in acute hippocampal slices
78 from *db/db* and wt littermates and investigated the effect of bath application of the GABA_A
79 receptor agonist isoguvacine (10μM, 2 min) on their neuronal firing (Figure 1A). Consistent
80 with the known depolarizing action of GABA in the newborn hippocampus (Ben Ari et al.,
81 2007), isoguvacine increased the firing of wt CA3 pyramidal neurons from P1 to P6 (Fig. 1
82 B). Remarkably, in *db/db* mice, the excitatory action of isoguvacine was only observed at P1
83 (Figure 1B). As early as P3, isoguvacine decreased the firing of the CA3 pyramidal *db/db*
84 neurons (Figure 1B). At P15, the effect of isoguvacine on the firing of the CA3 pyramidal
85 neurons was similar in wt and *db/db* mice (Figure 1B). Next to determine whether the
86 depolarizing-to-hyperpolarizing GABA developmental sequence was affected, we
87 investigated the reversal potential of evoked GABA_A receptor-mediated postsynaptic currents
88 (eGABA_A-PSCs) in *db/db* and wt littermates from P1 to P20 using gramicidin perforated
89 voltage-clamp recording to prevent disruption of intracellular chloride concentration ($[Cl^-]_i$).
90 GABA_A-PSCs were evoked in the presence of the glutamatergic receptor antagonists; NBQX
91 (5μM) and D-APV (40μM) while voltage clamping the neurons at various potentials (Figure
92 1C). In wt CA3 neurons, the reversal potential of eGABA_A-PSCs (E_{GABA}) shifted from
93 depolarizing to hyperpolarizing values during the second postnatal week of life (Fig. 1 D). In
94 *db/db* neurons, this shift occurred earlier, few days after birth (Figure 1D, at P3 E_{GABA} was -
95 38 ± 8 mV in wt and -64 ± 3 mV in *db/db* neurons, $P=0.023$, two-tailed unpaired Student's *t*-
96 *test*). In contrast the membrane potential at zero current was similar between wt and *db/db*

97 neurons at all age investigated (Figure 1D). Altogether, these data show that the emergence of
 98 GABAergic inhibition is advanced in leptin-receptor deficient mice *in vivo*.

99



100

101 **Figure 1: Early GABA developmental sequence in leptin-receptor deficient mice.**

102 (A) Cell attached recordings of CA3 pyramidal neurons on acute hippocampal slices. Scale bar, 2 min, 50pA.
 103 Corresponding time course of spike frequency changes are shown under each trace. (B) Developmental changes
 104 of isoguvacine action on spike activity. Mean \pm SEM. (C) Current-voltage relationships for evoked GABAergic
 105 synaptic currents. Insets : examples of GABAergic synaptic current evoked at holding potentials ranging from -
 106 110 to -60 mV (10 mV increment) in *db/db* and from -70 to -30 (10 mV increment) in wt CA3 pyramidal neuron.
 107 Scale bar, 10 ms, 20pA. (D) Developmental changes in E_{GABA} and E_m at zero current. Mean \pm SEM. In *B* and *D*,
 108 the number of cells recorded and number of mice used are indicated in parenthesis; # P <0.05 when compared to
 109 pre-isoguvacine values, two-tailed paired Student's *t*-test, * P <0.05, ** P <0.01 and *** P <0.001 when compared
 110 to age matched wt, two-tailed unpaired Student's *t*-test. (E) Developmental profile of plasma leptin levels in the
 111 wt (blue circle) and developmental profile of ΔE_{GABA} (gray circle). ΔE_{GABA} was calculated as the difference in
 112 E_{GABA} values between the wt and *db/db* at each developmental stage depicted in *D*. Numbers in parenthesis
 113 indicate the number of mice used. Mean + SEM. § P <0.05 when compared to P0 plasma leptin values, * P <0.05
 114 and ** P <0.01 when compared to P0 ΔE_{GABA} values, one way ANOVA followed by a Tukey's *post hoc* test. (F)
 115 Left: representative immuno-blots for hippocampal panKCC2 and β 3-tubulin in wt and *db/db* mice (first two
 116 lanes). The third lane (-) illustrates background (empty well). Right: box plots of normalized pan KCC2 in P6 wt

117 and *db/db* hippocampi. Numbers in parenthesis indicate the number of mice used. * $P < 0.05$, two-tailed unpaired
118 Student's *t*-test.

119
120 To further link leptin with the GABA sequence, we investigated the developmental
121 profile of plasma leptin levels in wt mice. We found that circulating leptin levels were low at
122 birth in wt, rose to a peak by the end of the first postnatal week and declined to low levels
123 during the third postnatal week of life (Figure 1E). Interestingly, this developmental profile of
124 leptin levels paralleled the developmental difference in E_{GABA} observed between wt and *db/db*
125 neurons (Figure 1D,E). Therefore, leptin levels surge during a critical developmental window
126 in wt mice, and E_{GABA} is impaired during this critical window in *db/db* mice. However
127 correlation does not mean causality. To address this point we used, newborn leptin-deficient
128 (*ob/ob*) mice. We found that *ob/ob* mice also exhibit an advanced emergence of GABAergic
129 inhibition *in vivo*, an effect partially restored by subcutaneous recombinant leptin injections to
130 mimic the leptin surge occurring in wt mice *in vivo* (Figure 1-figure supplement 1).
131 Altogether, these data show that leptin surge controls chloride homeostasis and the emergence
132 of functional GABAergic inhibition *in vivo*.

133 The developmental switch in GABA polarity is mainly due to the functional
134 expression of KCC2 (Medina et al., 2014; Rivera et al., 1999). We therefore assessed mRNA
135 expression of this Cl⁻ co-transporter in wt and *db/db* mice at P6 using quantitative qRT-PCR
136 from isolated hippocampi. KCC2 mRNA levels were enhanced in *db/db* hippocampi
137 compared to wt (from 1.6 ± 0.1 in wt to 2.6 ± 0.3 in *db/db* mice, $n=6$ for both, $P=0.038$, two-
138 tailed unpaired Student's *t*-test, not shown). In contrast, NKCC1 mRNA levels were not
139 altered (1.1 ± 0.2 and 1.2 ± 0.2 in respectively wt and *db/db* mice, $n=6$ for both, $P=0.7$, two-
140 tailed unpaired Student's *t*-test, not shown). To determine whether increased mRNA levels
141 results in increased expression of KCC2, we assessed KCC2 protein levels in P6 hippocampi
142 by western blotting. KCC2 protein expression was up-regulated in *db/db* hippocampi

143 compared to wt ($+33\pm 6$ %, $n=6$ wt and 5 db/db hippocampi, $P=0.02$ two-tailed unpaired
144 Student's t -test, Figure 3F). Immuno-labeling confirmed that KCC2 protein expression was
145 up-regulated in *db/db* hippocampi at P6 compared to wt (Figure 1-figure supplement 2).
146 KCC2 expression was also up-regulated in *ob/ob* hippocampi compared to wt (from
147 0.38 ± 0.07 to 0.97 ± 0.24 when normalized to $\beta 3$ tubulin, $n=6$ for both, $P=0.04$, two-tailed
148 unpaired Student's t -test, not shown). NKCC1 expression was however similar between wt
149 and *db/db* neurons (the NKCC1/ $\beta 3$ tubulin ratio was 0.56 ± 0.01 and 0.55 ± 0.02 in respectively
150 wt ($n=3$) and *db/db* ($n=3$) mice, $P=0.8$ two-tailed unpaired Student's t -test, Supplementary
151 File 1). Thus a deficit in leptin signaling leads to an earlier expression of KCC2 and an
152 advanced GABA switch to inhibition *in vivo*.


153

154 **Leptin controls chloride homeostasis *in vitro*.**

155 We next asked whether leptin directly acts on hippocampal cells to control Cl⁻
156 homeostasis. To address this point, we first evaluated the effect of a transient exposure to
157 leptin (100 nM, 24h) on Cl⁻ homeostasis on hippocampal cultures in immature neurons (6
158 DIV) when KCC2 activity is low, and in more mature neurons (15 DIV) when KCC2 activity
159 is high and GABA had switched to hyperpolarized values (Friedel et al., 2015). Using
160 gramicidin perforated voltage-clamp recordings; we assessed the reversal potential of GABA_A
161 receptor-mediated currents (E_{GABA}) induced by brief focal applications of isoguvacine in the
162 presence of the NKCC1 blocker bumetanide (10 μ M), to exclude cross regulation between the
163 2 co-transporters. We found that leptin treatment had no effect on E_{GABA} in immature neurons
164 ($E_{GABA} = -61\pm 1$ in control (19 neurons) and -61 ± 2 mV in leptin-treated (19 neurons) cultures,
165 3 cultures for both, Figure 2B), but induced a depolarizing shift of isoguvacine currents from -
166 99 ± 2 mV in control (21 neurons) to -85 ± 2 in leptin-treated (13 neurons) cultures (6 cultures

167 for both, $P=0.001$, ANOVA followed by a Tukey's *post hoc* test, Figure 2A,B). The leptin-
168 induced shift was abolished in neurons transfected with validated specific sh-RNAs (Dhar et
169 al., 2014) to silence the expression of the LepRb (Figure 2B). In neurons transfected with a
170 scramble shRNA, leptin was still able to depolarize E_{GABA} (Figure 2B). Treatment with the
171 selective KCC2 blocker VUO463271 (10 μ M) shifted E_{GABA} towards more depolarized values
172 and occluded the effect of leptin (Fig. 2 B). Leptin also decreased the rate of Cl^- extrusion by
173 KCC2 in cultured neurons preloaded with Cl^- , an effect mimicked by VUO463271 (Figure
174 2C,D). The half-recovery time was 194 ± 17 sec, 563 ± 143 sec and 625 ± 176 sec in respectively
175 control (n=7 neurons), leptin-treated (6 neurons, $P=0.018$ when compared to control, two-
176 tailed unpaired Student's *t*-test) and VUO463271-treated (n=4 neurons, $P=0.79$ when
177 compared to leptin-treated, two-tailed unpaired Student's *t*-test, Supplementary File 1)
178 cultures. These data therefore show that leptin acts on hippocampal leptin receptor to down
179 regulate KCC2 activity shifting E_{GABA} towards depolarizing values in hippocampal neuronal
180 cultures.

181



182

183

Figure 2: Leptin down-regulates KCC2 activity in cultured hippocampal neurons.

184

(A) I-V relationships for isoguvacine currents in vehicle (control) and leptin-treated (100nM, 24h) hippocampal

185

(15 DIV) cultures. Gramicidin perforated patch clamp recordings. Insets depict the isoguvacine currents. Scale

186

bar, 500 ms, 100 pA. (B) Box plots of E_{GABA} in the indicated conditions. * $P < 0.05$, ** $P < 0.01$, ANOVA followed

187

by a Tukey's *post hoc* test. (C) Examples of isoguvacine currents (arrow heads) recorded at -80 and -40 mV

188

before (t=-60 sec) and after (t=+20 and +420 sec) neuronal chloride loading in control neuronal culture (15

189

DIV). Gramicidin perforated patch clamp recordings. Scale bar, 100 pA, 40 mV, 1s. (D) Summary plots of

190

normalized E_{GABA} recovery after neuronal chloride loading in the indicated conditions. Mean \pm SEM. In B and D,

191

the number of cells recorded and number of cultures used are indicated in parenthesis.

192

193

194 We next asked whether leptin treatment altered KCC2 and NKCC1 expression.
195 Western blotting revealed that the expression of the two chloride co-transporters was
196 decreased in leptin-treated cultures (-85 ± 0.8 and -66 ± 0.6 % respectively, 5 cultures for both,
197 $P=2.01E-6$ and 0.0008 respectively, two-tailed unpaired Student's *t*-test, Figure 3D).
198 However, the ratio of the KCC2/NKCC1 protein was reduced following leptin treatment
199 (from 1.05 ± 0.19 to 0.49 ± 0.07 , $P=0.02$, two-tailed unpaired Student's *t*-test, Figure 3D).
200 Immuno-labeling confirmed that KCC2 protein was decreased in leptin-treated cultures
201 (Figure 1 – figure supplement 2).

202 The total amount of KCC2 protein is not an accurate indicator of its activity since, to
203 extrude Cl^- , KCC2 has to localize at the plasma membrane (Medina et al., 2014). We therefore
204 assessed the abundance of KCC2 expressed in different cell compartments of control and
205 leptin-treated cultured hippocampal neurons, using a KCC2 construct tagged in an external
206 loop with a fluorescent protein (KCC2-pH_{ext}) (Friedel et al., 2015). Combined with a
207 multistep immuno-labeling protocol, this construct allows to visualize the total amount of
208 KCC2-pH_{ext} expressed by neurons (F_t), the amount of KCC2-pH_{ext} present at the cell surface
209 (F_m) and the amount of KCC2-pH_{ext} internalized (F_i) (Figure 3A). F_t was similar in control
210 and leptin-treated cultured neurons (1.1 ± 0.13 vs 1.3 ± 0.18 a.u., 16 and 19 neurons
211 respectively, 3 cultures, $P=0.89$, ANOVA followed by a Tukey's *post hoc* test, not shown).
212 However, F_m was lower (1 ± 0.16 vs 0.44 ± 0.09 a.u., $P=0.0028$, ANOVA followed by a
213 Tukey's *post hoc* test) and F_i was higher (0.9 ± 0.18 vs 1.7 ± 0.15 a.u., $P=0.04$, ANOVA
214 followed by a Tukey's *post hoc* test) in leptin-treated cultures compared to control (Figure
215 3A,B). Both effects were abolished when the expression of LepRb was silenced with two
216 different specific sh-RNAs (Dhar et al., 2014) (Figure 3B). One batch of cultures was
217 routinely transfected with KCC2 construct tagged in the intracellular N-terminus with a
218 fluorescent protein as control experiment for cell membrane integrity during live-cell

219 immuno-labelling, (KCC2-pH_{int}, Figure 3A). The multistep immuno-labeling protocol didn't
220 detect membrane expressed or internalized KCC2-pH_{int} (Figure 3B). Altogether these data
221 show that leptin reduces the expression of KCC2 and its plasma membrane stability in
222 cultured hippocampal neurons.


223 The membrane expression and transport activity of KCC2 strongly depend on the
224 phosphorylated state of its intracellular C-terminus domain (Medina et al., 2014).
225 Phosphorylation on the threonine 906 and 1007 residues (T906, T1007) inhibits KCC2
226 activity and enhances KCC2 endocytosis, while phosphorylation of the serine 940 residue
227 (S940) enhances KCC2 activity (Medina et al., 2014). We therefore assessed the
228 phosphorylated state of KCC2 following leptin treatment in neuronal cultures. We found that
229 the total amount of phospho-T906 KCC2 (pKCC2 T906), phospho-T1007 KCC2
230 (pKCC21007) and phospho-S940 KCC2 (pKCC2S940) protein were decreased in leptin-
231 treated neuronal cultures (Figure 3C). However the ratio of pKCC2 T906 to total KCC2
232 protein (pKCC2T906/KCC2) and pKCC2 T1007 to total KCC2 protein
233 (pKCC2T1007/KCC2) were increased hence showing that the relative expression of these
234 phosphorylated forms of KCC2 were increased by leptin treatment: the pKCC2T906/KCC2
235 ratio increased from 1.1 ± 0.1 to 2.2 ± 0.08 , and the pKCC2T1007/KCC2 ratio increased from
236 1.4 ± 0.2 to 2.9 ± 0.3 ($P=0.0003$ and $P=0.004$ respectively, two-tailed unpaired Student's *t*-test,
237 5 independent neuronal cultures, Figure 3C,E). The relative expression of phospho-S940,
238 calculated as the ratio of pKCC2 S940 to total KCC2 protein (pKCC2S940/KCC2) was
239 however not modified (the ratio of pKCC2S940/KCC2 was 0.77 ± 0.02 in control and
240 0.083 ± 0.03 in leptin-treated cultures, $P=0.26$, two-tailed unpaired Student's *t*-test, 5
241 independent neuronal cultures, Figure 3C,E). These results show that leptin treatment alters
242 the phosphorylated state of KCC2 in hippocampal neuronal cultures.

243

244 WNK1 activity is required for KCC2 T906 and T1007 phosphorylation (Inoue et al.,
245 2012; Friedel et al., 2015). To test whether WNK1 is involved in the leptin-induced regulation
246 of chloride homeostasis we expressed previously validated specific sh-RNA (Friedel et al.,
247 2015) to silence WNK1 expression (sh-WNK) or constitutively active WNK1 mutant (WNK-
248 CA) in hippocampal neuronal cultures and measured E_{GABA} from gramicidin-perforated
249 patch-clamp recordings after 24h of vehicle or leptin (100 nM) treatment (Figure 3F). In
250 scramble expressing neurons, leptin treatment led to a depolarizing shift of E_{GABA} from -93 ± 2
251 to -80 ± 3 mV, $n=8$ and 20 neurons respectively, $P=0.001$, one way ANOVA followed by a
252 Tukey's *post hoc* test, Figure 3F). Genetic silencing of WNK1 prevented the depolarizing
253 shift of E_{GABA} induced by leptin-treatment ($P=0.89$ compared to control sh-WNK expressing
254 neurons, one way ANOVA followed by a Tukey's *post hoc* test, Figure 3F). In contrast,
255 expressing WNK1-CA produced a depolarizing shift of E_{GABA} ($E_{GABA}=-75 \pm 3.5$ mV, $P=0.001$,
256 one way ANOVA followed by a Tukey's *post hoc* test when compared to scramble expressing
257 neurons) and occluded the leptin action ($P=0.89$, one way ANOVA followed by a Tukey's
258 *post hoc* test, Figure 3F). Altogether these data suggest that leptin modulates the activity of
259 KCC2 via a WNK1-dependent pathway in cultured hippocampal neurons.

260

261



262


263 **Figure 3: leptin reduces the plasma membrane expression of KCC2 and modulates its**
 264 **phosphorylation state in cultured hippocampal neurons.**

265 (A) Representative images illustrating total, membrane and internalized pools of KCC2 with external tag
 266 (KCC2-pH_{ext}) in vehicle and leptin-treated (100 mM, 24h) cultured hippocampal neurons expressing a scramble
 267 Sh-RNA (Sh-Sbl). Neurons expressing KCC2 with internal tag (KCC2-pH_{int}) were proceeded in parallel
 268 experiments to ensure that immunocytochemistry on living neurons does not permeabilized the membrane. Scale
 269 bars 20 μ m and 1 μ m. (B) Box plots of normalized membrane (Fm) and internalized (Fi) fluorescence in vehicle
 270 and leptin-treated (+Lep) cultured neurons expressing the indicated constructs. * $P < 0.05$, one way ANOVA
 271 followed by a Tukey's *post hoc* test. (C) Western blots and quantifications (D and E) of KCC2, NKCC1,
 272 KCC2/NKCC1 ratio and the threonine 906, threonine 1007 and serine 940-phosphorylated forms of KCC2 in
 273 control and leptin (100nM, 24h)-treated hippocampal neuronal cultures (DIV15, five independent neuronal
 274 cultures). *** $P < 0.001$, two-tailed unpaired Student's *t-test*. (F) Box plots of E_{GABA} in the indicated conditions.
 275 Gramicidin perforated patch clamp recordings were performed on hippocampal neuronal cultures at 15 DIV.
 276 ** $P < 0.01$, *** $P < 0.001$, one way ANOVA followed by a Tukey's *post hoc* test. In B and F, the number of cells
 277 recorded and number of cultures used are indicated in parenthesis.

278 **Maternal obesity and neonatal hyperleptinemia delay the emergence of GABAergic**
279 **inhibition.**

280 Maternal obesity causes excess of leptin in offspring (Valleau and Sullivan, 2014;
281 Tessier et al., 2013). We therefore asked whether maternal obesity may affect the GABA
282 developmental sequence in the offspring. Female mice were fed with normal (ND) or high fat
283 (HFD) diet (Figure 4-figure supplement 1). After 6 weeks, females were mated and
284 maintained under their respective diet during the gestation and lactation period. Pups of HFD-
285 induced obese dams (DIO-pups) showed higher levels of serum leptin compared to offspring
286 of ND dams (ND-pups) (16 ± 1 ng/ml (n=6) vs 32 ± 4 ng/ml (n=4) in respectively P10-P15 ND-
287 pups and DIO-pups, $P=0.0049$, two-tailed unpaired Student's *t*-test, not shown). We
288 investigated the effect of bath applied isoguvacine on the firing of CA3 hippocampal slices.
289 We found that the excitatory-to-inhibitory switch of isoguvacine actions was delayed by about
290 one week in DIO-pups compared to ND-pups (Figure 4A,B). Thus, isoguvacine increased the
291 neuronal firing in ND-pups at P5 and decreased it starting from P10. In HFD-pups,
292 isoguvacine increased the firing frequency up to P13. To assess whether hyperleptinemia
293 mimicked the effect of maternal obesity, wt pups were treated with sub-cutaneous injections
294 of recombinant leptin (5mg/kg, twice a day) from P2 to P10. At P10-11, isoguvacine
295 decreased the neuronal firing of CA3 pyramidal neurons in vehicle-treated mice but not in
296 leptin-treated mice (Figure 4C,D).

297 Further, western blot analysis revealed that the expression of KCC2 was decreased in
298 DIO-pups compared to ND-pups (-51 ± 12 %, $P=0.03$, two-tailed unpaired Student's *t*-test,
299 Figure 4E,F) and in leptin-treated mice compared to vehicle-treated mice (-65 ± 7 %, $P=0.03$,
300 two-tailed unpaired Student's *t*-test, Figure 4 E,F). Thus, hyperleptinemia as maternal obesity
301 delays the GABA developmental sequence and down regulates KCC2 expression in offspring.



302

303

Figure 4: Hyperleptinemia and maternal obesity delay the GABA developmental sequence and downregulate KCC2 expression.

304

305 (A) Cell attached recordings of CA3 pyramidal neurons on acute hippocampal slices obtained from pups of
 306 normal diet (ND) and diet-induced obese (DIO) dams at P10. (B) Developmental changes of isoguvacine action
 307 on spike frequency. Mean + SEM. (C) Cell attached recordings of CA3 pyramidal neurons on acute hippocampal
 308 slices obtained from vehicle-treated (sham) and leptin-treated mice at P10. (D) Box plots of isoguvacine action
 309 on spike activity. In B and D, number of cells recorded and number of mice used are indicated in parenthesis;
 310 #P<0.05 when compared to pre-isoguvacine values, two-tailed paired Student's *t*-test and *P<0.05 and **P<0.01
 311 when compared to age matched ND-pups (B and C) or sham-pups (E), two-tailed unpaired Student's *t*-test. (E)
 312 Representative immuno-blots for hippocampal panKCC2 and β3-tubulin in offspring of DIO and ND dams at
 313 P13 and in control (sham) and leptin-treated (Lep) mice at P10. The third lanes (-) illustrate background (empty
 314 wells). (F) Normalized panKCC2 immunoreactivity in ND (n=6 pups) and sham (n=3 pups), in offspring of DIO
 315 (n=5 pups) and in leptin-treated mice (n=5 pups). Mean + SEM. *P<0.05, two-tailed unpaired Student's *t*-test.

316

317

318

319 **DISCUSSION**

320 Our data demonstrate that leptin is a key factor in setting the direction of GABA_A
321 receptor-mediated signaling in the developing hippocampus. We show that leptin exposure of
322 hippocampal cultures leads to a depolarizing shift of GABA_A receptor mediated responses
323 and down-regulates KCC2 expression and membrane stability. Furthermore, in the absence of
324 leptin signaling, hippocampal neurons show an early expression of KCC2 and an advanced
325 development of GABAergic inhibition *in vivo*. Conversely, excess leptin down regulates the
326 expression of KCC2 and delays the emergence of GABAergic inhibition *in vivo*. Previous
327 studies have reported that the GABA switch is delayed in mice lacking oxytocin (Tyzio et al.,
328 2006; Leonzino et al., 2016) or the thyroid hormones (Friauf et al., 2008; Sawano et al.,
329 2013). Thus, the functional maturation of GABAergic synapses depends on an optimal and
330 timely balance level of hormones that accelerate (oxytocin, thyroid hormones) or retard
331 (leptin) the GABA switch.

332

333 We have shown that leptin regulates the activity of KCC2 at the transcriptional and
334 post-translational levels *in vivo*. The downstream pathway linking the long-form leptin
335 receptor b (LepRb) and the functional expression of KCC2 remains to be elucidated.
336 However, our data suggest that early in development, leptin surge promotes the
337 phosphorylation of the threonine 906 and 1007 (T906/T1007) residues of KCC2 and reduces
338 its membrane expression and activity via a WNK1-dependent pathway. This pathway seems
339 to be quite specific in mediating leptin action, as we did not detect any changes in the
340 phosphorylation of Ser940, a residue phosphorylated/dephosphorylated under other
341 circumstances via protein kinase C (Lee et al., 2011). As development progresses, when leptin
342 levels return to low level, the WNK1-dependent inhibitory action of KCC2 activity is

343 removed allowing the depolarizing-to-hyperpolarizing transition of GABA actions in the
344 developing rodent hippocampus. Our model is supported by several lines of evidence
345 obtained *in vitro*. We have shown that genetic silencing or activation of WNK1 respectively
346 prevents or occludes the effect of leptin on E_{GABA} . Moreover, we have shown that leptin
347 treatment does not affect E_{GABA} in immature cultured neurons, at a developmental stage when
348 the activity of KCC2 is low and the activity of the WNK-pathway is high (Friedel et al.,
349 2015). Finally, we have shown that leptin enhances the phosphorylation of the T906/T1007
350 residues of KCC2, promotes the endocytosis of KCC2 and decreases its membrane
351 expression. Of note, WNK1-regulated de-phosphorylation of the T906/1007 residues of
352 KCC2 contributes to the depolarizing-to-hyperpolarizing GABA sequence in the developing
353 hippocampus (Inoue et al., 2012; Friedel et al., 2015). Alanine substitutions of the
354 T906/T1007 residues within the C-terminus of KCC2, mimicking a dephosphorylated state of
355 KCC2, yield to hyperpolarized reversal potentials of GABA in neuronal cultures, ranging
356 between -90 to -100 mV (Titz et al., 2015), i.e. the same order of magnitude to the values
357 observed in *db/db* neurons (Figure 1D). Thus, the lack of leptin signaling in *db/db* and *ob/ob*
358 mice may prevent the developmental WNK1-regulated changes in T906/T1007 KCC2
359 phosphorylation *in vivo*, thereby leading to an advanced emergence of GABA inhibition in the
360 newborn rodent hippocampus.

361 Rodent studies show that the ability of GABA to depolarize immature neurons plays
362 an essential role in the assembly of functional networks during development (Ben-Ari et al.,
363 2012). Advanced GABAergic inhibition or premature expression of KCC2 lead to long
364 lasting disturbance of glutamatergic and GABAergic inputs and behavioral abnormalities in
365 adult mice (Wang and Kriegstein, 2008; Wang and Kriegstein, 2011; Deidda et al., 2015;
366 Cancedda et al., 2007; Chudotvorova et al., 2005). Accordingly, hippocampal network
367 formation and function are impaired in *db/db* mice (Guimond et al., 2014; Harvey, 2013; Van

368 Doorn et al., 2017). However, it is impossible to ascertain whether the early emergence of
369 GABA inhibition is a direct cause of these abnormal behaviors since leptin also directly
370 impacts many aspect of brain development (Guimond et al., 2014; Harvey, 2013; Bouret,
371 2010) that may contribute to behavioral deficit in *db/db* mice.

372 Although translating animal research to the human situation is difficult, the GABA
373 developmental sequence and leptin surge occurring during the second postnatal week of life
374 in mouse are shifted towards fetal stage in humans (Chen and Kriegstein, 2015; Sedmak et al.,
375 2016; Valteau and Sullivan, 2014). This seems in contradiction with the classical satiety
376 function of leptin since during pregnancy nutrients availability should be enhanced to
377 optimize fetal growth. However, animal studies suggest the existence of a pregnancy-induced
378 leptin resistance of the mother's brain and accumulating evidence indicate that leptin has
379 numerous actions before birth on fetal growth (Briffa et al., 2015). Importantly, leptin
380 deficiency in this period is associated with long term consequences such as cognitive defects,
381 anxiety, and depression. Conversely, leptin replacement alleviates these symptoms,
382 suggesting that leptin is a crucial factor in brain development and mental health (Wang et al.,
383 2016; Rivera et al., 2015). Thus, during pregnancy, leptin may act beyond its classical satiety
384 role and operates as an important developmental signal of fetal brain development.

385 Our data also indicate that excess leptin delays the GABA switch in offspring.
386 Defective chloride homeostasis primes the brain to malfunction contributing to autistic-like
387 phenotypes associated with neurological disorders (Tyzio et al., 2014; He et al., 2014; Deidda
388 et al., 2015; Banerjee et al., 2016). Moreover, it is noticeable that bumetanide treatment, that
389 restores low $[Cl^-]_I$ and alleviates autistic-like symptoms in rodents (Tyzio et al., 2014;
390 Banerjee et al., 2016), also improves the symptoms of ASD in humans (Lemonnier et al.,
391 2017). The ability of leptin to regulate chloride homeostasis may therefore have important
392 implications in health, but also in the emergence of neurological disorders associated with

393 abnormal GABAergic transmission. ASD are often associated with higher levels of leptin in
394 circulation (Rodrigues et al., 2014; Rodrigues et al., 2014; Lisik et al., 2016). Interestingly,
395 maternal obesity which is associated with hyperleptinemia (Valleau and Sullivan, 2014;
396 Tessier et al., 2013) increases the risk of developing mental and behavioral disorders in
397 offspring (Wang et al., 2016; Rivera et al., 2015), such as attention deficit hyperactivity
398 disorder (ADHD), ASD, anxiety, depression, schizophrenia and impairments in cognition,
399 which among many modifications, are associated with altered GABAergic transmission .
400 Animal models of maternal high-fat diet induced obesity also document persistent changes in
401 offspring behavior such as hyperactivity, impairments in social behavior, depressive-like
402 behaviors and diminished cognition (Rivera et al., 2015).

403

404 In conclusion, optimal levels of leptin are critical during development for a timely
405 emergence of GABAergic inhibition. Epidemiological studies showed that the prevalence of
406 obesity among childbearing age women has steadily increased during the past 20 years in
407 most developed nations (An and Xiang, 2016; Flegal et al., 2012). Leptin thus lies at the
408 crossroad between neurological, metabolic and nutritional disorders that may arise from
409 societal changes in lifestyle, stress level and eating behaviors.

410

411 MATERIAL and METHODS

**Key Resources
Table**

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
genetic reagent (<i>M. musculus</i>)	B6.Cg-Lepob/J	The Jackson Laboratory	RRID:IMSR_JAX:000632	
genetic reagent (<i>M. musculus</i>)	B6.BKS-Leprdb	The Jackson Laboratory	RRID:IMSR_JAX:000697	
Transfected DNA construct	shLepR 3426	PMID:24877561, DOI: 10.1210/me.2013-1332		Dr. G. Wayman (Washington State University)
transfected DNA construct	shLepR 3299	PMID:24877561, DOI: 10.1210/me.2013-1332		Dr. G. Wayman (Washington State University)
transfected DNA construct	WNK shRNA	PMID: 26126716, DOI: 10.1126/scisignal.aaa0354		
transfected DNA construct	WNK-CA	PMID: 26126716, DOI: 10.1126/scisignal.aaa0354		
transfected DNA construct	KCC2-pHluorin	PMID: 24928908, DOI: 10.15252/embr.201438840		
antibody	Mouse anti- β 3 tubulin	Sigma-Aldrich	RRID:AB_477590, Cat# T8660	WB (1:10 000)
antibody	Rabbit anti-KCC2	US Biological	RRID:AB_2188802, Cat# K0120-07	WB (1:2000)
antibody	Donkey anti-chicken Alexa488	Fluoprobes	RRID: AB_2686906, Cat# FP-SA5110	IHC (1:1000)
antibody	Chicken anti-MAP2	Abcam	RRID:AB_2138153, Cat# ab5392	IHC (1:2000)
antibody	Donkey Anti-rabbit Cy3	Chemicon	RRID:AB_92588, Cat# AP182C	IHC (1:1000)
antibody	mouse Anti-GFP	Novus Biologicals	RRID:AB_531011, Cat# NB 600-597	
antibody	NKCC1 total	the Division of Signal Transduction Therapy Unit (DSTT) at the University of Dundee	dundee (S022D)	WB (1mg/ml)
antibody	pan KCC2			Dr. C. Rivera (University of Helsinki)
antibody	KCC2 Ser940	Novus Biologicals	Cat# NBP2-29513	WB (1mg/ml)
antibody	KCC2a phosphoT1007	the Division of Signal Transduction Therapy Unit (DSTT) at the University of Dundee	dundee (S959C)	WB (1mg/ml)
antibody	KCC2a phosphoT906	the Division of Signal Transduction Therapy Unit (DSTT) at the University of Dundee	dundee (S959C)	WB (1mg/ml)
Oligonucleotides	Slc12a2 (NKCC1)	Qiagen	QT00197785	
Oligonucleotides	Slc 12a5 (KCC2)	Qiagen	QT00145327	
Oligonucleotides	GAPDH	Qiagen	QT001199633	
peptide, recombinant protein	Recombinant murine leptin	Tocris,	Cat# TO-2985/1	

commercial assay or kit	Mouse leptin ELISA kit	BioVendor R & DR	Cat# RD291001200	
chemical compound, drug	1,2,3,4-Tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX)	NIMH Chemical Synthesis and Drug Supply Program, https://nimh-repository.rti.org/		
chemical compound, drug	D-2-amino-5-phosphovaleric acid (D-APV)	NIMH Chemical Synthesis and Drug Supply Program, https://nimh-repository.rti.org/		
chemical compound, drug	1,2,3,4-Tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX)	NIMH Chemical Synthesis and Drug Supply Program, https://nimh-repository.rti.org/		
chemical compound, drug	Isoguvacine	Tocris	Cat# 0235	
chemical compound, drug	VU0463271	Tocris	Cat# 4719	
chemical compound, drug	Bumetanide	Sigma	Cat# B3023	
Software and Algorithms	National Institutes of Health		RRID:SCR_003070	
Software and Algorithms	Synaptosoft, http://www.synaptosoft.com/MiniAnalysis/DownloadDemo.html			

412

413 **Animals**

414 All animal procedures were carried out in accordance with the European Union Directive of
415 22 September (2010/63/EU). Experiments were performed on both male and female postnatal
416 day (P) 4 and 5 Wistar rats and P1 to P20 C57BL/6 transgenic mice lacking leptin (ob/ob) or
417 leptin receptor (db/db) expression (purchased from Charles River Laboratory, Italy). Control
418 experiments were performed on wild type (wt) littermates. Animals were housed in a
419 temperature-controlled environment with a 12 light/dark cycle and free access to food and
420 water. Mice were genotyped following the Jackson Laboratory genotyping protocol (strains
421 B6.Cg-Lep^{ob}/J, ID 000632 and B6.BKS-Lepr^{db}, ID 000697). For each experiment, tissues
422 from littermate wt and KO mice were prepared and the persons assessing and quantifying the
423 outcomes were blinded to the genotype of the mice.

424 To assess the effect of maternal obesity, 8 weeks old C57BL/6 female were fed with a high-
425 fat diet (HFD, 60% kcal from fat, D12492, Research Diet) or a normal diet (ND, 10% kcal
426 from fat, D12450B, Research Diet) during 6 weeks at the end of which they were weighed
427 and mated. All female were maintained during gestation and lactation on the same diet
428 received before.

429

430 **Leptin injection**

431 Recombinant murine leptin was reconstituted in PBS buffer pH 7.4, and injected (5mg/kg)
432 sub-cutaneous in wt and *ob/ob* pups twice a day at 9-10h a.m and 5-6h p.m. Control received
433 same volume injections of vehicle, pH 7.4.

434

435 **Leptin immunoassay**

436 The plasma samples were centrifuged (10.000rpm, 10 min, 4°C) immediately after collection
437 of arteriovenous blood samples obtained from 0 to 20 days old wt and *db/db* mice at 10-11h
438 a.m. Plasma samples from leptin-treated mice (*ob/ob* and wt mice) were obtained 30 min to
439 1h after the last sub-cutaneous injection. Plasma was collected and stored at -80°C.
440 Quantification of endogenous leptin was performed with Mouse Leptin ELISA Kit
441 (BioVendor R&D) in the concentrated solutions following the manufacturer's protocol. The
442 measured concentration of samples was calculated from the standard curve and expressed as
443 ng/ml.

444

445 **Hippocampal slice preparation and electrophysiological recordings**

446 Brains were removed and immersed into ice-cold (2-4°C) artificial cerebrospinal fluid
447 (ACSF) with the following composition (in mM): 126 NaCl, 3.5 KCl, 2 CaCl₂, 1.3 MgCl₂,
448 1.2 NaH₂PO₄, 25 NaHCO₃ and 11 glucose, pH 7.4 equilibrated with 95% O₂ and 5% CO₂.
449 Hippocampal slices (600 μm thick) were cut with a McIlwain tissue chopper (Campden
450 Instruments Ltd.) and kept in ACSF at room temperature (25°C) for at least one hour before
451 recording. Slices were then transferred to a submerged recording chamber perfused with
452 oxygenated (95% O₂ and 5% CO₂) ACSF (3 ml/min) at 34°C.

453 E_{GABA} measurement: Perforated patch-clamp recordings were made from CA3 pyramidal
454 neurons using an axopatch 200B (Axon Instrument) or Multiclamp 700B (Molecular devices)
455 amplifier. Glass recording electrodes had resistances of 4-7 MΩ when filled with KCl solution
456 containing 150mM KCl and 10 mM HEPES, pH adjusted to 7.2 with Tris-OH. The pipettes
457 were tip filled with a gramicidin-free KCl solution and then backfilled with the same solution
458 containing gramicidin A (50μg/ml, diluted from a 50mg/ml stock solution in DMSO). After
459 the access resistance had dropped (40 to 80 MΩ) and stabilized (15-30 min), a current-voltage
460 relationship was constructed by measuring the peak amplitude of averaged evoked
461 GABAergic synaptic current (3 single sweeps) at different holding potentials in 10 mV
462 increment recorded in the presence of glutamatergic receptor antagonists (NBQX 5μM and D-
463 APV 40μM). Measurements were not corrected for the liquid junction potentials. A linear
464 regression was used to calculate the best-fit line of the voltage dependence of the synaptic
465 currents. Spontaneous rupture into whole-cell was evidenced by large inward synaptic
466 currents due to E_{Cl} of 0mV.

467 Isoguvacine effect on neuronal firing: Loose cell attached patch clamp recordings were
468 performed from CA3 pyramidal neurons using an axopatch 200B (Axon Instrument) with
469 glass electrodes (4-7 MΩ) filled with KCl solution containing 150mM KCl and 10 mM

470 HEPES, pH adjusted to 7.2 with Tris-OH. After a baseline period of at least 10 min in the
471 presence of NBQX (5 μ M) and D-APV (40 μ M), isoguvacine (10 μ M) was bath applied for 2
472 min. The effect of isoguvacine was quantified as the mean frequency of action potential
473 following application of isoguvacine (4-8 min) versus baseline frequency (-10-0 min).
474 Synaptic activity were recorded with Axoscope software version 8.1 (Axon Instruments) and
475 analyzed offline with Mini Analysis Program version 6.0 (Synaptosoft).

476

477 **Western Blotting**

478 Whole hippocampi were obtained from P5-6 mice as described above. Hippocampi were
479 homogenized in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS, 50 mM Tris HCl,
480 pH 8, containing proteinases and phosphatases inhibitors (Complete Mini, Roche). Lysates
481 were centrifuged (1.000g for 10 min at 4°C) and the supernatant was heated at 90°C for 5 min
482 with Laemmli loading buffer. Loading was 20 μ g of proteins as determined using a BCA
483 protein Assay Kit (Thermo Scientific). Proteins were separated in 7–15% SDS-PAGE and
484 electrophoretically transferred to nitrocellulose membranes. Membranes were blocked with
485 5% bovine serum albumin (BSA) in TBS 0.1% Tween 20 (TBST) for 2 h at RT, then
486 incubated with primary antibodies diluted in TBST containing 3% BSA overnight at 4°C or 2
487 h at RT. Blots were probed with antibody against KCC2 (1:2000; rabbit, US Biological) and
488 tubulin (1:10.000; β -tubulin, mouse, Sigma). After washing with TBST, membranes were
489 incubated with HRP-conjugated secondary antibodies diluted in TBST containing 3% BSA
490 for 60 min, washed with TBST, and then developed using the G:BOX gel imaging system
491 (Syngene). Expression levels were estimated by ImageJ software.

492

493 **Real-time qRT-PCR**

494 Whole hippocampi were obtained from P6 mice as described above. RNA was isolated and
495 quantified by reading the absorbance at 260 nm (NanoPhotometer, IMPLEN) using Mini
496 RNeasy kit (Qiagen), then converted to cDNA using 1 µg RNA and a QuantiTect Reverse
497 Transcription kit (Qiagen) according to manufacturer's instructions. PCR was carried out with
498 the LightCycler 480 SYBR Green I Master (Roche Applied Science) with 1 µL cDNA using
499 the following oligonucleotides (QuantiTect Primer Assays, Qiagen): NKCC1 (Slc12a2;
500 QT00197785), KCC2 (Slc12a5; QT00145327) and glyceraldehyde-3-phosphate
501 dehydrogenase (GAPDH, QT001199633). Quantitative RT-PCR was performed with a Roche
502 LC480 Light Cycler (Roche Applied Science) following the manufacturer's instructions.
503 Relative mRNA values were calculated using the LC480 software and GAPDH as the
504 housekeeping gene. PCR was performed in replicate of 3.

505

506 **Immuno-staining**

507 Brains were removed from P6 mice and fixed overnight at 4°C in 4% paraformaldehyde
508 (PFA). Brains were rinsed in phosphate buffer saline (PBS, 0.1M) and coronal sections (70
509 µM thick) were obtained using a vibratome (Microm HVM 650V). Section were incubated
510 first for 1h in PBS with 1% bovine serum albumin (BSA) and 0.3% Triton X-100, then
511 overnight at 4°C with a rabbit anti-panKCC2 primary antibody (1:4000; non commercial, gift
512 from Dr. C. Rivera). Sections were rinsed in PBS and incubated for 2h with an Alexa Fluor
513 488 donkey anti-rabbit secondary antibody (1:1000, FluoProbes). Sections were
514 counterstained for Nissl bodies, rinsed in PBS and mounted on microscope slides using
515 Vectashield mounting medium (Vector). Immuno-reactivity was visualized using a laser
516 scanning confocal microscope (LSM 510 Meta, Zeiss) with a 20X air objective and a 63X oil

517 immersion objective. Optical sections were digitized (1024 x 1024 pixels) and processed
518 using ImageJ software (National Institutes of Health, <http://rsb.info.nih.gov/ij/>). Analysis of
519 the intensity of the distribution of KCC2 fluorescence was performed at high magnification
520 ($\times 63$ objective) using the Image J program. The same straight line length ($3\mu\text{m}$) was applied
521 from the nucleus to the external cell compartment. The Plot profile values were analyzed and
522 we normalized the fluorescence intensity to the highest intensity of the control condition. The
523 intensity of KCC2 staining in neuronal cells was expressed as the mean ratio of
524 KCC2/Neurotracer staining intensity.

525

526 **Primary cultures, transfection of rat hippocampal neurons, electrophysiological**
527 **recordings, live cell immuno-labelling, Immuno-staining and Immunoprecipitation with**
528 **phosphorylation site-specific antibodies**

529

530 Hippocampi from 18-day-old rat embryos were dissected and dissociated using trypsin
531 (0.05%) and plated at a density of 70,000 cells cm^{-2} in minimal essential medium (MEM)
532 supplemented with 10% Nu-Serum (BD Biosciences), 0.45% glucose, 1 mM sodium
533 pyruvate, 2 mM glutamine, and penicillin-streptomycin (10 IU ml^{-1}) as previously described
534 (23). On days 7, 10, and 13 of culture incubation (DIV, days *in vitro*), half of the medium was
535 changed to MEM with 2% B27 supplement (Invitrogen). For electrophysiology neuronal
536 cultures were plated on coverslips placed in 35-mm culture dishes. Twenty-four hours before
537 plating, dishes with coverslips were coated with polyethylenimine (5 mg/ml).

538 For the analysis of KCC2 immuno-staining, KCC2-GFP clusters and electrophysiological
539 experiments, pyramidal neurons were selected based on their morphology (Benson et al.,
540 1994).

541 **Gramicidin-perforated patch-clamp recordings** were performed at 23-24°C as previously
542 reported (Friedel et al., 2015) (details are in supporting information). Series resistance was
543 monitored routinely at a V_h of -80 mV with 5-mV hyperpolarizing pulses, typically taking 10
544 to 15 min for the series resistance to stabilize at 15 to 60 M Ω). Data were low pass-filtered at
545 2 kHz and acquired at 10 kHz. Isoguvacine (30 mM) was focally applied (50 to 150 ms,
546 10,000 to 30,000 Pa) to the neuron soma and proximal dendrites through a micropipette
547 connected to a Picospritzer (General Valve Corporation). Isoguvacine responses were
548 recorded at voltages -120, -100, -80, and -60 mV. A linear regression was used to calculate
549 the best-fit line of the voltage dependence of the synaptic currents. For analysis of Cl⁻
550 extrusion kinetic all neurons were overloaded with identical amount of [Cl⁻]_i resulting in
551 $E_{GABA} = -40$ mV (~30 mM of [Cl⁻]_i). This was achieved by repetitive three-pulse applications
552 of isoguvacine (100 ms pulses with interval 500 ms) at 0 mV followed by a single
553 isoguvacine application (100 ms) at -40 mV until disappearance of the outwardly directed
554 isoguvacine-induced current at -40 mV. This later corresponded to $E_{GABA} = -40$ mV. 20 sec
555 after the loading protocol, a pair of 100 ms isoguvacine pulses at -40 mV and -80 mV
556 (interval 500 ms) was applied every 10 s to monitor the E_{GABA} . For quantification of Cl⁻
557 extrusion kinetic, E_{GABA} at each time point was first normalized to the mean control, pre-
558 loading E_{GABA} values. These normalized values were then normalized to the normalized
559 E_{GABA} obtained 20 sec after the loading protocol (-49 ± 2 mV for control experiments, n=7
560 neurons, 3 cultures).

561 For **transfection of cultures** growing in 35-mm dishes, 300 ml of Opti-MEM was mixed with
562 7 ml of Lipofectamine 2000 (Invitrogen), 1 ml of Magnetofection CombiMag (OZ
563 Biosciences), and 1 to 1.5 mg of different pcDNAs premixed in desired proportions. The
564 mixture was incubated for 20 min at room temperature and thereafter distributed dropwise
565 above the neuronal culture. Culture dishes were placed on a magnetic plate (OZ Biosciences)

566 and incubated for 30 to 35 min at 37°C. Transfection was terminated by the substitution of
567 90% of the incubation solution with fresh culture medium. The experiments were based on
568 cotransfection into the same cell of two different pcDNAs encoding a fluorescent marker of
569 transfection (eGFP, 0.3 µg), shRNAs (1.2 µg) against leptin receptor or WNK1, scrambled
570 shRNAs or WNK1 construct. We used two shRNAs targeting different regions on the LepRb
571 gene. The efficacy of these shRNAs has been tested in a previous study on human kidney
572 cells and cultured hippocampal neurons (Dhar et al., 2014). The efficacy of the WNK1
573 construct and shRNA has been tested in a previous study in PC-12 and N2a cell line and
574 cultured hippocampal neurons (Friedel et al., 2015).

575 For **immunocytochemistry on living neurons**, rabbit anti-GFP antibody were diluted in
576 culture medium and applied to neurons for 2 hours at 37°C, 5% CO₂. Neurons were then
577 rinsed three times for 10 min at room temperature with HEPES-buffered saline solution
578 containing 150 mM NaCl, 2.5 mM KCl, 2.0 mM MgCl₂, 2.0 mM CaCl₂, 20 mM HEPES, and
579 10 mM D-glucose (pH 7.4), labeled with anti-rabbit Cy3-conjugated antibody (dissolved in
580 the HEPES buffered saline) for 20 min at 13°C and fixed in Antigenfix (Diapath). To reveal
581 intracellular pool of live-labelled proteins, cells were subsequently permeabilized with 0.3%
582 Triton X-100, blocked by 5% goat serum and incubated during 1 h at room temperature (RT)
583 with anti-rabbit Alexa 647-conjugated antibody. Then, for visualization of the entire pool of
584 overexpressed KCC2-pH_{ext} cells were labeled overnight (4°C) with mouse anti-GFP antibody
585 and for 1 hour at RT with anti-mouse Alexa 488-conjugated antibody. For control of the cell
586 integrity during live-cell immunolabelling, one batch of cultures were routinely transfected
587 with KCC2 construct harboring phluorine tag linked to the intracellular N-terminus of the
588 transporter.

589 Images of labeled cells were acquired with an Olympus Fluorview-500 confocal microscope
590 (oil-immersion objectives 40x, (NA1.0) or 60x (NA1.4); zoom 1-5). We randomly selected
591 and focused on a transfected cell by only visualizing Alexa-488 fluorescence and then
592 acquired Z-stack images of Alexa-488, CY3 and Alexa-647 fluorochromes emitted
593 fluorescence using, respectively green (excitation 488 nm, emission 505-525 nm), red
594 (excitation 543 nm emission 560-600 nm) and infra-red (excitation 633, emission >660 nm)
595 channels of the microscope. Each Z-stack included 10 planes of 1 μm optical thickness and
596 taken at 0.5 μm distance between planes. The cluster properties and fluorescence intensities of
597 each cell were analyzed with Metamorph software. First, we used the logical “NOT”
598 conversion of pairs of Alexa-647 and CY3 images to isolate in each focal plane the Alexa-647
599 signal that was not overlapping with CY3 fluorescence restricted to plasma membrane. This
600 gave rise to additional images reflecting the fluorescence of the internalized pool of labeled
601 clusters, called thereafter “NOT-conversion”. Second, the arithmetic summation for each Z-
602 stack and channel was performed to collect the whole fluorescence of the different signals
603 (Alexa-488 = total protein fluorescence; CY3 = plasma membrane restricted fluorescence;
604 NOT-conversion = internalized restricted fluorescence; Alexa-647 = all surface labeled
605 fluorescence). Third, a binary mask was created for each cell from Alexa-488 image to isolate
606 the signal coming from the transfected neuron, and the fluorescence parameters (total
607 fluorescence, single cluster fluorescence as well as density and brightness of clusters) were
608 analyzed for each channel (Alexa-488, CY3, NOT-conversion and Alexa-647) in regions
609 overlapping with the binary mask. The analysis parameters were the same for each
610 experiment and all experiments were done blind. After analysis, data were normalized to the
611 mean value of cells transfected with KCC2-pHext + scrambled shRNA.

612 For **immuno-staining**, hippocampal cultures ($75,000 \text{ cells/cm}^2$, DIV 14) were fixed in 4%
613 PFA-sucrose for 10 min. Coverslips were washed in PBS for 15 min and incubated in 0.2 M

614 glycine for 10 min. Blocking was done in 1% BSA/0.5% Triton X-100 in PBS for 30 min to
615 permeabilize cells and reduce nonspecific binding. Cultures were washed and incubated with
616 a rabbit anti-panKCC2 (1:4000; non commercial , gift from Dr. C. Rivera) coupled to chicken
617 anti-MAP2 (1:2000, Microtubule-associated protein 2, Sigma) antibodies in PBS overnight at
618 4°C. Primary antibodies were visualized after staining with the appropriate goat anti-rabbit
619 and anti-donkey IgG conjugated to Cy3 (1:1000, chemicon) and Alexa488 (1:1000,
620 FluoProbes), respectively in 1% BSA/PBS for 60 min. Cultures were washed and coverslips
621 mounted using Vectashield (Vector). Sequential acquisition of immunoreactivity was
622 visualized using laser scanning confocal microscope (Zeiss LSM 510 Meta) with a x63 oil-
623 immersion objective. In each image, laser light levels and detector gain and offset were
624 adjusted to avoid any saturated levels. Confocal micrographs are digital composites of a Z-
625 series scan of 4 – 6 optical sections through a depth of 4 – 5 μ m.

626

627 For the **immunoprecipitation with phosphorylation site-specific antibodies**, KCCs
628 phosphorylated at the KCC2 Thr906 and Thr1007 equivalent residue were immuno-
629 precipitated from clarified control and leptin (100nM, 24h) treated-hippocampal culture
630 lysates (centrifuged at 16,000g at 4°C for 20 min) using phosphorylation site-specific
631 antibody coupled to protein G-Sepharose. The phosphorylation site-specific antibody was
632 coupled with protein G-Sepharose at a ratio of 1 mg of antibody per 1 ml of beads in the
633 presence of lysate (20 mg/ml) to which the corresponding nonphosphorylated peptide had
634 been added. Two milligrams of clarified cell lysate was incubated with 15 mg of antibody
635 conjugated to 15 ml of protein G-Sepharose for 2 hours at 4°C with gentle agitation. Beads
636 were washed three times with 1 ml of lysis buffer containing 0.15 M NaCl and twice with 1
637 ml of buffer A. Bound proteins were eluted with 1 \times LDS sample buffer.

638 Cell lysates (15 mg) in SDS sample buffer were subjected to electrophoresis on
639 polyacrylamide gels and transferred onto nitrocellulose membranes. The membranes were
640 incubated for 30 min with TTBS containing 5% (w/v) skim milk. The membranes were then
641 immunoblotted in 5% (w/v) skim milk in TTBS with the indicated primary antibodies
642 overnight at 4°C. Antibodies prepared in sheep were used at a concentration of 1 to 2 mg/ml.
643 The incubation with phosphorylation site-specific sheep antibodies was performed with the
644 addition of the non-phosphorylated peptide antigen (10 mg/ml) used to raise the antibody. The
645 blots were then washed six times with TTBS and incubated for 1 hour at room temperature
646 with secondary HRP-conjugated antibodies diluted 5000-fold in 5% (w/v) skim milk in
647 TTBS. After repeating the washing steps, the signal was detected with the enhanced
648 chemiluminescence reagent. Immunoblots were developed by ChemiDoc™ Imaging
649 Systems (Bio-Rad). Figures were generated using Photoshop and Illustrator (Adobe). The
650 relative intensities of immunoblot bands were determined by densitometry with ImageJ
651 software.

652 Antibodies used for western blots were raised in sheep and affinity-purified on the appropriate
653 antigen by the Division of Signal Transduction Therapy Unit (DSTT) at the University of
654 Dundee; other antibodies were purchased. NKCC1 total (S022D, first bleed, raised against
655 residues 1-288 of human NKCC1); KCC2a phosphoT906 (S959C, first bleed; raised against
656 residues 975–989 of human KCC3a phosphorylated at T991, SAYTYER(T)LMMEQRSRR);
657 KCC2a phosphoT1007 (S961C, first bleed; raised against residues 1032–1046 or 1041–1055
658 of human KCC3a phosphorylated at T1048). KCC2 Ser940 antibody (NBP2-29513, Novus
659 Biologicals). KCC2 total antibody (S700C, first bleed; raised against residues 1–119 of
660 human KCC2A); The anti-β-Tubulin III (neuronal) antibody (T8578) was purchased from
661 Sigma-Aldrich. Secondary antibodies coupled to horseradish peroxidase used for

662 immunoblotting were obtained from Pierce. IgG used in control immunoprecipitation
663 experiments was affinity-purified from pre-immune serum using Protein G-Sepharose.

664
665 **Reagents**

666 The following reagents were purchased from the indicated sources: 1,2,3,4-Tetrahydro-6-
667 nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX) and D-2-amino-5-
668 phosphovaleric acid (D-APV) from the Molecular, Cellular, and Genomic Neuroscience
669 Research Branch (MCGNRB) of the National Institute of Mental Health (NIMH, Bethesda,
670 MD, USA). Leptin, Isoguvacine and VU0463271 from Tocris Cookson (Bristol, UK).
671 Bumetanide from Sigma (St Louis, MO, USA).

672

673 **Statistics**

674 No statistical methods were used to predetermine sample sizes, but our sample sizes
675 correspond to those reported in previous publications (Tyzio et al., 2006; Dhar et al 2014;
676 Friedel et al., 2015). To ensure the consistency and reproducibility of our results, we
677 conducted repeated trials in different cell cultures, acute brain slice and hippocampi prepared
678 from at least three different animals for each experimental condition. In this study, the
679 persons performing experiments and analyzing the data were blinded to the genotype of the
680 mice. These include electrophysiological recordings on acute slices, western blot, and PCR.
681 The one way ANOVA followed by a Tukey's *post hoc* test was used for multiple comparisons
682 between experimental conditions. A two-tailed unpaired Student's *t*-test was used to analyze
683 difference between two individual groups. A two-tailed paired Student's *t*-test was used to
684 analyze differences within one group across conditions, i.e. frequency of action potential
685 before and after isoguvacine. All data are expressed as Mean \pm standard error to the mean

686 (S.E.M.). Data are judged significantly different when $P < 0.05$. Statistical information is
687 provided in the figures, figure legends and text.

688

689 **Supplementary figures legends**

690 **Figure 1-figure supplement 1: Leptin controls GABA signaling in the mice hippocampus**
691 ***in vivo*.**

692 (A) Plasma leptin levels in P8 wt, *ob/ob* and leptin-treated *ob/ob* mice (*ob* + lep, 5mg/kg twice a day sub-
693 cutaneous from P3 to P8, n=4, blood samples were collected 30 min after the last injection). (B) Box plot of
694 isoguvacine action on spike frequency in wt mice, *ob/ob* and leptin-treated *ob/ob* mice at P8. (C,D) Box plots of
695 E_{GABA} and E_m at zero current in 4 wt mice, *ob/ob* and leptin-treated *ob/ob* CA3 pyramidal neurons. The cells
696 recorded and number of animal used are indicated in parenthesis * $P < 0.05$, ** $P < 0.01$, one way ANOVA followed
697 by a Tukey's *post hoc* test.

698

699 **Figure 1-figure supplement 2: KCC2 expression in *db/db* hippocampal neurons in vivo**
700 **and leptin-treated hippocampal neuronal cultures in vitro.**

701 (A) Confocal images showing KCC2 immuno-labeling in the CA3 pyramidal layer of wt and *db/db* hippocampi
702 at P6. (B) Summary plot of the normalized KCC2 fluorescence intensity ratio in P6 wt and *db/db* hippocampal
703 CA3 pyramidal layer. Calibration bar 20 μ m. 3 wt and *db/db* littermate animals. mean +/- sem. ** $p < 0.01$, two-
704 tailed unpaired Student's *t*-test. (C) Examples of KCC2 and MAP2 immunostaining in control and leptin-treated
705 (100 nM, 24h) cultured hippocampal neurons (15 DIV). Scale bar 20 μ M. (C) Summary plots of the normalized
706 KCC2 fluorescence intensity in control (n=30) and leptin-treated (n=45) hippocampal neurons. Pooled data from
707 3 different cultures.

708 **Figure 1-figure supplement 3: Raw blots for panel F (WT and db).**

709

710 **Figure 4-figure supplement 1: High fat diet induced obesity.**

711 (A) Experimental overview. (B) Body weight curves of adult (8 weeks old) female mice fed with normal diet
712 (10% kcal from fat, ND white symbols, n=4) or a high fat diet (60% kcal from fat, HFD, n=12). (C) Average
713 body weight increase after 6 weeks of food supply. * $P < 0.05$, ** $P < 0.01$, two-tailed unpaired Student's *t*-test.

714 **Figure 4-figure supplement 2: Raw blots for panel E (ND and DIO).**

715 **Figure 4-figure supplement 3: Raw blots for panel E (Lep and sham).**

716

717
718
719
720
721
722
723
724
725
726
727

728

729
730
731

Acknowledgments

We thank Dr. Y. Ben-Ari for helpful support and suggestions during this study; Drs. R. Cossart and N. Kourdougli for reading of the manuscript and Drs. E. Cherubini, C. Rivera and E. Sernagor for helpful critical comments on the study. This work was supported by the Ministère de la Recherche et de l'Enseignement Supérieur, Neurochlore (CD) and the National Institutes of Health (Grant MH086032, GW).

732
733

Reference List

- 734 1. **Leptin**
735 Ahima R. S., Flier J. S. (2000)
736 *Annu. Rev. Physiol* **62**: 413-437.
737 DOI: 10.1146/annurev.physiol.62.1.413
- 738 2. **Age-period-cohort analyses of obesity prevalence in US adults**
739 An R., Xiang X. (2016)
740 *Public Health* **141**: 163-169.
741 DOI:10.1016/j.puhe.2016.09.021
- 742 3. **Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical**
743 **processing in Rett syndrome.**
744 Banerjee A., Rikhye R. V., Breton-Provencher V., Tang X., Li C., Li K., Runyan C. A.,
745 Fu Z., Jaenisch R., Sur M. (2016)
746 *Proc. Natl. Acad. Sci. U. S A* **113**: 7284-7296.
747 DOI:10.1073/pnas.1615330113
- 748 4. **GABA: a pioneer transmitter that excites immature neurons and generates**
749 **primitive oscillations**
750 Ben Ari Y., Gaiarsa J. L., Tyzio R., Khazipov R. (2007)
751 *Physiol Rev.* **87**: 1215-1284.
752 DOI:10.1152/physrev.00017.2006
- 753 5. **Refuting the challenges of the developmental shift of polarity of GABA actions:**
754 **GABA more exciting than ever!**
755 Ben-Ari Y., Woodin M. A., Sernagor E., Cancedda L., Vinay L., Rivera C., Legendre
756 P., Luhmann H. J., Bordey A., Wenner P., Fukuda A., Van den Pol A. N., Gaiarsa J. L.,
757 Cherubini E. (2012)
758 *Front Cell Neurosci.* **6**: 1-18.
759 DOI: 10.3389/fncel.2012.00035
- 760 6. **Characterization of GABAergic neurons in hippocampal cell cultures**
761 Benson D. L., Watkins F. H., Steward O., Banker G. (1994)
762 *J. Neurocytol.* **23**: 279-295
- 763 7. **Long-term plasma levels of leptin and adiponectin in Rett syndrome**
764 Blardi P., de Lalla A., D'Ambrogio T., Vonella G., Ceccatelli L., Auteri A., Hayek J.
765 (2009)
766 *Clin. Endocrinol. (Oxf)* **70**: 706-709.
767 DOI:10.1111/j.1365-2265.2008.03386.x
- 768 8. **Neurodevelopmental actions of leptin**
769 Bouret S. G. (2010)
770 *Brain Res.* **1350**: 2-9.
771 DOI: 10.1016/j.brainres.2010.04.011
- 772 9. **Trophic action of leptin on hypothalamic neurons that regulate feeding**
773 Bouret S. G., Draper S. J., Simerly R. B. (2004)





- 774 *Science* **304**: 108-110.
775 DOI: 10.1126/science.1095004
- 776 10. **Leptin in pregnancy and development: a contributor to adulthood disease?**
777 Briffa J. F., McAinch A. J., Romano T., Wlodek M. E., Hryciw D. H. (2015)
778 *Am J Physiol Endocrinol Metab* **308**: 335-350.
779 Medline doi:10.1152/ajpendo.00312.2014
- 780 11. **Excitatory GABA action is essential for morphological maturation of cortical**
781 **neurons in vivo**
782 Cancedda L., Fiumelli H., Chen K., Poo M. M. (2007)
783 *J. Neurosci.* **27**: 5224-5235.
784 DOI: 10.1523/JNEUROSCI.5169-06.2007
- 785 12. **A GABAergic projection from the zona incerta to cortex promotes cortical neuron**
786 **development.**
787 Chen J., Kriegstein A. (2015)
788 *Science* **350**: 554-558.
789 DOI:10.1126/science.aac6472
- 790 13. **Early expression of KCC2 in rat hippocampal cultures augments expression of**
791 **functional GABA synapses**
792 Chudotvorova I., Ivanov A., Rama S., Hubner C. A., Pellegrino C., Ben Ari Y., Medina
793 I. (2005)
794 *J. Physiol* **566**: 671-679.
795 DOI: 10.1113/jphysiol.2005.089821
- 796 14. **Restoring GABAergic inhibition rescues memory deficit in a Huntington's**
797 **disease mouse model**
798 Dargaei Z., Bang J. Y., Mahadevan V., Khademullah C. S., Bedard S., Parfitt G. M.,
799 Kim J. C., Woodin M. A. (2018)
800 *Proc. Natl. Acad. Sci. U. S A* **115**: 1618-1626.
801 DOI: 10.1073/pnas.1716871115
- 802 15. **Reversing excitatory GABAAR signaling restores synaptic plasticity and memory**
803 **in a mouse model of Down syndrome**
804 Deidda G., Parrini M., Naskar S., Bozarth I. F., Contestabile A., Cancedda L. (2015)
805 *Nat. Med.* **21**: 318-326.
806 DOI:10.1038/nm.3827
- 807 16. **Leptin induces hippocampal synaptogenesis via CREB-regulated microRNA-132**
808 **suppression of p250GAP**
809 Dhar M., Zhu M., Impey S., Lambert T. J., Bland T., Karatsoreos I. N., Nakazawa T.,
810 Appleyard S. M., Wayman G. A. (2014)
811 *Mol. Endocrinol.* **28**: 1073-1087.
812 DOI: 10.1210/me.2013-1332
- 813 17. **GABA and glutamate pathways are spatially and developmentally affected in the**
814 **brain of Mecp2-deficient mice**
815 El-Khoury R., Panayotis N., Matagne V., Ghata A., Villard L., Roux J. C. (2014)
816 *PLoS. One.* **9**: e92169.





- 817 DOI:10.1371/journal.pone.0092169
- 818 18. **Prevalence of obesity and trends in the distribution of body mass index among Us**
819 **adults, 1999-2010**
820 Flegal K. M., Carroll M. D., Kit B. L., Ogden C. L. (2012)
821 *JAMA* **307**: 491-497.
822 DOI:10.1001/jama.2012.39
- 823 19. **Hypothyroidism impairs chloride homeostasis and onset of inhibitory**
824 **neurotransmission in developing auditory brainstem and hippocampal neurons**
825 Friauf E., Wenz M., Oberhofer M., Nothwang H. G., Balakrishnan V., Knipper M.,
826 Lohrke S. (2008)
827 *Eur. J Neurosci.* **28**: 2371-2380.
828 DOI:10.1111/j.1460-9568.2008.06528.x
- 829 20. **WNK1-regulated inhibitory phosphorylation of the KCC2 cotransporter maintains**
830 **the depolarizing action of GABA in immature neurons**
831 Friedel P., Kahle K. T., Zhang J., Hertz N., Pisella L. I., Buhler E., Schaller F., Duan J.,
832 Khanna A. R., Bishop P. N., Shokat K. M., Medina I. (2015)
833 *Sci. Signal.* **8**: ra65.
834 DOI:10.1126/scisignal.aaa0354
- 835 21. **Leptin potentiates GABAergic synaptic transmission in the developing rodent**
836 **hippocampus**
837 Guimond D., Diabira D., Porcher C., Bader F., Ferrand N., Zhu M., Appleyard S. M.,
838 Wayman G. A., Gaiarsa J. L. (2014)
839 *Front Cell Neurosci.* **8**: 1-17.
840 DOI: 10.3389/fncel.2014.00235
- 841 22. **Leptin regulation of neuronal morphology and hippocampal synaptic function**
842 Harvey J. (2013)
843 *Front Synaptic. Neurosci.* **5**: 1-7.
844 DOI: 10.3389/fnsyn.2013.00003
- 845 23. **The developmental switch in GABA polarity is delayed in fragile X mice**
846 He Q., Nomura T., Xu J., Contractor A. (2014)
847 *J. Neurosci.* **34**: 446-450.
848 DOI:10.1523/JNEUROSCI.4447-13.2014
- 849 24. **Taurine inhibits K⁺-Cl⁻ cotransporter KCC2 to regulate embryonic Cl-**
850 **homeostasis via with-no-lysine (WNK) protein kinase signaling pathway**
851 Inoue K., Furukawa T., Kumada T., Yamada J., Wang T., Inoue R., Fukuda A. (2012)
852 *J. Biol. Chem.* **287**: 20839-20850.
853 DOI: 10.1074/jbc.M111.319418
- 854 25. **NMDA receptor activity downregulates KCC2 resulting in depolarizing GABA_A**
855 **receptor-mediated currents**
856 Lee H. H., Deeb T. Z., Walker J. A., Davies P. A., Moss S. J. (2011)
857 *Nat. Neurosci.* **14**: 736-743.
858 DOI: 10.1038/nn.2806

- 859 26. **Effects of bumetanide on neurobehavioral function in children and adolescents**
860 **with autism spectrum disorders**
861 Lemonnier E., Villeneuve N., Soni S., Serret S., Rosier A., Roue M., Brosset P.,
862 Viellard M., Bernoux D., Rondeau S., Thummler S., Ravel D., Ben Ari Y. (2017)
863 *Transl. Psychiatry* **7**.
864 Medline doi:10.1038/tp.2017.10
- 865 27. **The Timing of the Excitatory-to-Inhibitory GABA Switch Is Regulated by the**
866 **Oxytocin Receptor via KCC2**
867 Leonzino M., Busnelli M., Antonucci F., Verderio C., Mazzanti M., Chini B. (2016)
868 *Cell Rep.* **15**: 96-103.
869 DOI:10.1016/j.celrep.2016.03.013
- 870 28. **Plasma levels of leptin and adiponectin in fragile X Syndrome.**
871 Lisik M. Z., Gutmajester E., Sieron A. L. (2016)
872 *NeuroImmunoModulation* **23**: 239-243.
873 DOI:10.1159/000452336
- 874 29. **Current view on the functional regulation of the neuronal K(+)-Cl(-) cotransporter**
875 **KCC2**
876 Medina I., Friedel P., Rivera C., Kahle K. T., Kourdougli N., Uvarov P., Pellegrino C.
877 (2014)
878 *Front Cell Neurosci.* **8**: 27.
879 DOI:10.3389/fncel.2014.00027
- 880 30. **Is there more to gaba than synaptic inhibition?**
881 Owens D. F., Kriegstein A. R. (2002)
882 *Nat. Rev. Neurosci.* **3**: 715-727.
883 DOI: 10.1038/nrn919
- 884 31. **The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal**
885 **maturation**
886 Rivera C., Voipio J., Payne J. A., Ruusuvuori E., Lahtinen H., Lamsa K., Pirvola U.,
887 Saarma M., Kaila K. (1999)
888 *Nature* **397**: 251-255.
889 DOI:10.1038/16697
- 890 32. **The role of maternal obesity in the risk of neuropsychiatric disorders**
891 Rivera H. M., Christiansen K. J., Sullivan E. L. (2015)
892 *Front Neurosci.* **9**: 1-10.
893 DOI: 10.3389/fnins.2015.00194
- 894 33. **Changes in adipokine levels in autism spectrum disorders**
895 Rodrigues D. H., Rocha N. P., Sousa L. F., Barbosa I. G., Kummer A., Teixeira A. L.
896 (2014)
897 *Neuropsychobiology* **69**: 6-10.
898 DOI:10.1159/000356234
- 899 34. **Simultaneous two-photon imaging of intracellular chloride concentration and pH**
900 **in mouse pyramidal neurons in vivo**


- 901 Sato S. S., Artoni P., Landi S., Cozzolino O., Parra R., Pracucci E., Trovato F.,
902 Szczurkowska J., Luin S., Arosio D., Beltram F., Cancedda L., Kaila K., Ratto G. M.
903 (2017)
904 *Proc. Natl. Acad. Sci. U. S A* **114**: 8770-8779.
905 DOI: 10.1073/pnas.1702861114
- 906 35. **Thyroid hormone-dependent development of the GABAergic pre- and post-**
907 **synaptic components in the rat hippocampus**
908 Sawano E., Takahashi M., Negishi T., Tashiro T. (2013)
909 *Int. J Dev. Neurosci.* **31**: 751-761.
910 DOI:10.1016/j.ijdevneu.2013.09.007
- 911 36. **Developmental expression patterns of KCC2 and functionally associated molecules**
912 **in the human brain.**
913 Sedmak G., Jovanov-Milisevic N., Puskarjov M., Ulamec M., Kruslin B., Kaila K.,
914 Judas M. (2016)
915 *Cereb. Cortex* **26**: 4574-4589.
916 DOI:10.1093/cercor/bhv218
- 917 37. **Role of leptin in pregnancy: Consequences of maternal obesity**
918 Tessier D. R., Ferraro Z. M., Gruslin A. (2013)
919 *Placenta* **34**: 205-211.
920 DOI:10.1016/j.placenta.2012.11.035
- 921 38. **Could tuning of the inhibitory tone involve graded changes in neuronal chloride**
922 **transport?**
923 Titz S., Sammler E. M., Hormuzdi S. G. (2015)
924 *Neuropharmacol.* **95**: 321-331.
925 DOI: 10.1016/j.neuropharm.2015.03.026
- 926 39. **Maternal oxytocin triggers a transient inhibitory switch in GABA signaling in the**
927 **fetal brain during delivery**
928 Tyzio R., Cossart R., Khalilov I., Minlebaev M., Hubner C. A., Represa A., Ben-Ari Y.,
929 Khazipov R. (2006)
930 *Science* **314**: 1788-1792.
931 DOI:10.1126/science.1133212
- 932 40. **Oxytocin-mediated GABA inhibition during delivery attenuates autism**
933 **pathogenesis in rodent offspring**
934 Tyzio R., Nardou R., Ferrari D. C., Tsintsadze T., Shahrokhi A., Eftekhari S., Khalilov
935 I., Tsintsadze V., Brouchoud C., Chazal G., Lemonnier E., Lozovaya N., Burnashev N.,
936 Ben-Ari Y. (2014)
937 *Science* **343**: 675-679.
938 DOI:10.1126/science.1247190
- 939 41. **The impact of leptin on perinatal development and psychopathology**
940 Valteau J. C., Sullivan E. L. (2014)
941 *J. Chem. Neuroanat.* **61**: 232.
942 DOI:10.1016/j.jchemneu.2014.05.001
- 943 42. **leptin resistance and hippocampal deficits**

- 944 Van Doorn C., Macht V. A., Grillo C. A., Reagan L. P. (2017)
945 *Physiology and Behavior* **176**: 207-213.
946 DOI: 10.1016/j.physbeh.2017.03.002
- 947 43. **GABA regulates excitatory synapse formation in the neocortex via NMDA receptor**
948 **activation**
949 Wang D. D., Kriegstein A. R. (2008)
950 *J. Neurosci.* **28**: 5547-5558
- 951 44. **Blocking early GABA depolarization with bumetanide results in permanent**
952 **alterations in cortical circuits and sensorimotor gating deficits**
953 Wang D. D., Kriegstein A. R. (2011)
954 *Cereb. Cortex* **21**: 574-587.
955 DOI: 10.1093/cercor/bhq124
- 956 45. **Maternal body mass index and risk of autism spectrum disorders in offspring: A**
957 **meta-analysis**
958 Wang Y., Tang S., Xu S., Weng S., Liu Z. (2016)
959 *Sci. Rep.* **6**: 1-8.
960 DOI: 10.1038/srep34248
961
962

A**B****C****D**




db WT ladder (-)






KCC2

db WT ladder (-)




Tubulin


A**B****C**

Row blots Figure 4E

KCC2




tubulin



Row blots Figure 4E

KCC2



tubulin

